the epidemiologic burden of non‐alcoholic fatty liver disease across the world
L Henry, J Paik, ZM Younossi - Alimentary pharmacology & …, 2022 - Wiley Online Library
Background The prevalence of non‐alcoholic fatty liver disease (NAFLD) is increasing in
parallel with obesity and type 2 diabetes. Aim To review the global epidemiology of NAFLD …
parallel with obesity and type 2 diabetes. Aim To review the global epidemiology of NAFLD …
Epidemiology, pathogenesis, diagnosis and emerging treatment of nonalcoholic fatty liver disease
E Makri, A Goulas, SA Polyzos - Archives of medical research, 2021 - Elsevier
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, with an
estimated rising prevalence, in concert with the epidemics of obesity and type 2 diabetes …
estimated rising prevalence, in concert with the epidemics of obesity and type 2 diabetes …
Lean NAFLD: a distinct entity shaped by differential metabolic adaptation
Conclusions This study demonstrates that E. multilocularis can induce T‐cell exhaustion
through inhibitory receptor TIGIT, and that blocking this checkpoint may reverse the …
through inhibitory receptor TIGIT, and that blocking this checkpoint may reverse the …
Geographical similarity and differences in the burden and genetic predisposition of NAFLD
NAFLD has become a major public health problem for more than 2 decades with a growing
prevalence in parallel with the epidemic of obesity and type 2 diabetes (T2D). The disease …
prevalence in parallel with the epidemic of obesity and type 2 diabetes (T2D). The disease …
Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease according to body mass index …
Methods A total of 560 patients (28 lean, 174 overweight, 229 obese, 89 severely obese, 40
morbidly obese) were included. Diagnostic performances and optimal cut-off values for FIB …
morbidly obese) were included. Diagnostic performances and optimal cut-off values for FIB …
Role of intensive dietary and lifestyle interventions in the treatment of lean nonalcoholic fatty liver disease patients
Methods In total, 35 patients (14 lean and 21 obese) were included in the study. All patients
underwent transient elastography examinations, and controlled attenuation parameter …
underwent transient elastography examinations, and controlled attenuation parameter …
[HTML][HTML] Non-alcoholic fatty liver disease: A growing public health problem in Turkey
Non-alcoholic fatty liver disease (NAFLD) is histologically classified as either non-alcoholic
fatty liver or non-alcoholic steatohepatitis (NASH). NASH is the progressive subtype of …
fatty liver or non-alcoholic steatohepatitis (NASH). NASH is the progressive subtype of …
Fatty liver through the ages: nonalcoholic steatohepatitis
ZM Younossi, L Henry - Endocrine Practice, 2022 - Elsevier
Objective The global epidemic of obesity and type 2 diabetes mellitus is the main driver of
the growing global prevalence of nonalcoholic fatty liver disease (NAFLD). We aimed to …
the growing global prevalence of nonalcoholic fatty liver disease (NAFLD). We aimed to …
[HTML][HTML] Metabolic-associated Fatty Liver Disease: Time to integrate ground-breaking new terminology to our clinical practice?
CO Demirtas, Y Yilmaz - Hepatology Forum, 2020 - ncbi.nlm.nih.gov
To address these issues, an international expert panel consensus was recently reached by
32 distinguished experts from 22 countries to propose a more comprehensive redefinition of …
32 distinguished experts from 22 countries to propose a more comprehensive redefinition of …
[HTML][HTML] The utility of noninvasive scores in non-alcoholic fatty liver disease patients with normal and elevated serum transaminases
Results FIB-4 cutoffs of< 1.3 and< 1.45 for low risk of advanced fibrosis had a sensitivity of
70% and 54% in patients with elevated transaminases and 70% and 52% in patients with …
70% and 54% in patients with elevated transaminases and 70% and 52% in patients with …